Verena Dzialas

Verena Dzialas

Auto-generated profile, based on publicly available information

Verena Dzialas

Department of Nuclear Medicine, Faculty of Medicine, and University Hospital Cologne University of Cologne Cologne Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2022 in Movement Disorders
Verified
Journal Article
Open access
MBMagdalena Banwinkler
Magdalena Banwinkler
VDVerena Dzialas
Verena Dzialas
TIThe Parkinson'S Progression Markers Initiative
The Parkinson'S Progression Markers Initiative
MHMerle C. Hoenig
Merle C. Hoenig
TEThilo Van Eimeren
Thilo Van Eimeren
Background: α‐Synuclein pathology is associated with neuronal degeneration in Parkinson's disease (PD) and considered to sequentially spread across the brain (Braak stages). According to a new hypothesis of distinct α‐synuclein spreading directions based on the initial site of pathology, the “brain‐first” spreading subtype would be associated with a more asymmetric cerebral and nigrostriatal pathology than the “body‐first” subtype.Objective: Here, we tested if proposed markers of brain‐first PD (ie, higher dopamine transporter [DaT] asymmetry; absence of rapid eye movement sleep behavior disorder [RBD]) are associated with a greater or more asymmetric reduction in gray matter volume (GMV) in comparison to body‐first PD.Methods: Data of 255 de novo PD patients and 110 healthy controls (HCs) were retrieved from the Parkinson's Progression Markers Initiative. Structural magnetic resonance images were preprocessed, and GMVs and their hemispherical asymmetry were obtained for each of the neuropathologically defined Braak stages. Group and correlation comparisons were performed to assess differences in GMV and GMV asymmetry between PD subtypes.Results: PD patients demonstrated significantly smaller bilateral GMVs compared to HCs, in a pattern denoting stage‐dependent disease‐related brain atrophy. However, the degree of putaminal DaT asymmetry was not associated with reduced GMV or higher GMV asymmetry. Furthermore, RBD‐negative and RBD‐positive patients did not demonstrate a significant difference in GMV or GMV asymmetry.Conclusions: Our findings suggest that putative brain‐first and body‐first patients do not present diverging brain atrophy patterns. Although certainly not disproving the brain‐first/body‐first spreading hypothesis, this study fails to provide evidence in support of it. © 2022 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society

7 November 2022 in Movement Disorders
Verified
Journal Article
Open access
MHMerle C. Hoenig
Merle C. Hoenig
VDVerena Dzialas
Verena Dzialas
ADAlexander Drzezga
Alexander Drzezga
TEThilo Van Eimeren
Thilo Van Eimeren

5 September 2024 in Movement Disorders
Verified
Journal Article
Open access
VDVerena Dzialas
Verena Dzialas
EDElena Doering
Elena Doering
HEHelena Eich
Helena Eich
ASAntonio P. Strafella
Antonio P. Strafella
DVDavid E. Vaillancourt
David E. Vaillancourt
IGInternational Parkinson Movement Disorders Society‐Neuroimaging Study Group
International Parkinson Movement Disorders Society‐Neuroimaging Study Group
In recent years, many neuroimaging studies have applied artificial intelligence (AI) to facilitate existing challenges in Parkinson's disease (PD) diagnosis, prognosis, and intervention. The aim of this systematic review was to provide an overview of neuroimaging‐based AI studies and to assess their methodological quality. A PubMed search yielded 810 studies, of which 244 that investigated the utility of neuroimaging‐based AI for PD diagnosis, prognosis, or intervention were included. We systematically categorized studies by outcomes and rated them with respect to five minimal quality criteria (MQC) pertaining to data splitting, data leakage, model complexity, performance reporting, and indication of biological plausibility. We found that the majority of studies aimed to distinguish PD patients from healthy controls (54%) or atypical parkinsonian syndromes (25%), whereas prognostic or interventional studies were sparse. Only 20% of evaluated studies passed all five MQC, with data leakage, non‐minimal model complexity, and reporting of biological plausibility as the primary factors for quality loss. Data leakage was associated with a significant inflation of accuracies. Very few studies employed external test sets (8%), where accuracy was significantly lower, and 19% of studies did not account for data imbalance. Adherence to MQC was low across all observed years and journal impact factors. This review outlines that AI has been applied to a wide variety of research questions pertaining to PD; however, the number of studies failing to pass the MQC is alarming. Therefore, we provide recommendations to enhance the interpretability, generalizability, and clinical utility of future AI applications using neuroimaging in PD. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

27 March 2025 in Annals of Neurology
Verified
Journal Article
Open access
VDVerena Dzialas
Verena Dzialas
GBGérard N. Bischof
Gérard N. Bischof
KMKathrin Möllenhoff
Kathrin Möllenhoff
ADAlexander Drzezga
Alexander Drzezga
TEThilo Van Eimeren
Thilo Van Eimeren
Objective: Although dopamine transporter (DaT) imaging is a valuable diagnostic biomarker, few studies have investigated its utility in objectively monitoring disease progression in patients with Parkinson's disease (PD). To date, no study has established a longitudinal relationship between the DaT signal decline and the motor symptom increase, potentially due to neglected factors such as brain regions, disease laterality, and symptom subtypes, which this study addresses.Methods: This cohort study included participants who met the Movement Disorder Society (MDS) criteria for PD, with longitudinal imaging and clinical data from the Parkinson's Progression Markers Initiative Database. Linear mixed model analyses were used to investigate the relationship between the DaT signal decline and the motor symptom severity increase over time. We hypothesized that a decline in putaminal DaT availability in the less affected hemisphere would be associated with increasing contralateral motor symptoms, measured by the Unified Parkinson's Disease Rating Scale (UPDRS). Additional models explored the effects of different brain regions (caudate and putamen), symptom categories (MDS UPDRSIII score with and without tremor items), and disease onset laterality (left or right hemisphere).Results: We included 719 participants (443 male patients and 276 female patients; mean age = 62.2 ± 9.5 years) with 1,981 available data points. As hypothesized, we observed a significant association between the decrease in the less affected putaminal DaT signal and motor symptom increase in the contralateral body side, independent of including or excluding tremor scores.Interpretation: Our findings support the use of repetitive DaT imaging for objectively monitoring PD progression. This could facilitate personalized disease tracking, subtyping, and intervention testing in the future. ANN NEUROL 2025;98:120–135

28 June 2024 in Brain
Verified
Journal Article
Closed access
PDF file
MBMagdalena Banwinkler
Magdalena Banwinkler
VDVerena Dzialas
Verena Dzialas
LRLionel Rigoux
Lionel Rigoux
AAAdrian L Asendorf
Adrian L Asendorf
HTHendrik Theis
Hendrik Theis
TEThilo Van Eimeren
Thilo Van Eimeren
The relative inability to produce effortful movements is the most specific motor sign of Parkinson’s disease, which is primarily characterized by loss of dopaminergic terminals in the putamen. The motor motivation hypothesis suggests that this motor deficit may not reflect a deficiency in motor control per se, but a deficiency in cost-benefit considerations for motor effort. For the first time, we investigated the quantitative effect of dopamine depletion on the motivation of motor effort in Parkinson’s disease. A total of 21 early-stage, unmedicated patients with Parkinson’s disease and 26 healthy controls were included. An incentivized force task was used to capture the amount of effort participants were willing to invest for different monetary incentive levels and dopamine transporter depletion in the bilateral putamen was assessed. Our results demonstrate that patients with Parkinson’s disease applied significantly less grip force than healthy controls, especially for low incentive levels. Congruously, decrease of motor effort with greater loss of putaminal dopaminergic terminals was most pronounced for low incentive levels. This signifies that putaminal dopamine is most critical to motor effort when the trade-off with the benefit is poor. Taken together, we provide direct evidence that the reduction of effortful movements in Parkinson’s disease depends on motivation and that this effect is associated with putaminal dopaminergic degeneration.

2 May 2024 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
VDVerena Dzialas
Verena Dzialas
MHMerle C. Hoenig
Merle C. Hoenig
SPStéphane Prange
Stéphane Prange
GBGérard N. Bischof
Gérard N. Bischof
TIThe Parkinson’s Progression Marker Initiative
The Parkinson’s Progression Marker Initiative
TEThilo Van Eimeren
Thilo Van Eimeren
Resilience in neuroscience generally refers to an individual’s capacity to counteract the adverse effects of a neuropathological condition. While resilience mechanisms in Alzheimer’s disease are well-investigated, knowledge regarding its quantification, neurobiological underpinnings, network adaptations, and long-term effects in Parkinson’s disease is limited. Our study involved 151 Parkinson’s patients from the Parkinson’s Progression Marker Initiative Database with available Magnetic Resonance Imaging, Dopamine Transporter Single-Photon Emission Computed Tomography scans, and clinical information. We used an improved prediction model linking neuropathology to symptom severity to estimate individual resilience levels. Higher resilience levels were associated with a more active lifestyle, increased grey matter volume in motor-associated regions, a distinct structural connectivity network and maintenance of relative motor functioning for up to a decade. Overall, the results indicate that relative maintenance of motor function in Parkinson’s patients may be associated with greater neuronal substrate, allowing higher tolerance against neurodegenerative processes through dynamic network restructuring.